ArticleInfluenza and other respiratory viruses2026
A Cluster of Influenza A(H3N2) Viruses in 2024 From Tasmania, Australia, With Reduced Susceptibility to Baloxavir.
Saira Hussain, Charmaine Chia, Ashwin Muraleetharan, Yi-Mo Deng, Xiaomin Dong, Presa Chanthalavanh, Emi Takashita, Clyde Dapat, Jessica E Miller, Heidi Peck and 5 more
Abstract read
In one paragraphArticle in Influenza and other respiratory viruses, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
15 authors.
Saira HussainWHO Collaborating Centre for Reference and Research on Influenza, Victorian Infectious Diseases Reference Laboratory at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.ORCID https://orcid.org/0000-0002-0545-244X Ashwin MuraleetharanWHO Collaborating Centre for Reference and Research on Influenza, Victorian Infectious Diseases Reference Laboratory at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.ORCID https://orcid.org/0000-0002-0711-2529 Yi-Mo DengWHO Collaborating Centre for Reference and Research on Influenza, Victorian Infectious Diseases Reference Laboratory at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
Xiaomin DongWHO Collaborating Centre for Reference and Research on Influenza, Victorian Infectious Diseases Reference Laboratory at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.ORCID https://orcid.org/0000-0003-0302-9442 Presa ChanthalavanhWHO Collaborating Centre for Reference and Research on Influenza, Victorian Infectious Diseases Reference Laboratory at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
Emi TakashitaWHO Collaborating Centre for Reference and Research on Influenza, Influenza Research Center, National Institute of Infectious Diseases, Japan Institute for Health Security, Tokyo, Japan.ORCID https://orcid.org/0000-0002-9064-4699 Clyde DapatWHO Collaborating Centre for Reference and Research on Influenza, Victorian Infectious Diseases Reference Laboratory at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.ORCID https://orcid.org/0000-0002-7616-4680 Jessica E MillerWHO Collaborating Centre for Reference and Research on Influenza, Victorian Infectious Diseases Reference Laboratory at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.ORCID https://orcid.org/0000-0002-1806-1894 Heidi PeckWHO Collaborating Centre for Reference and Research on Influenza, Victorian Infectious Diseases Reference Laboratory at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.ORCID https://orcid.org/0000-0002-3651-2839 Jan WilliamsonPathology Department, Royal Hobart Hospital, Hobart, Tasmania, Australia.
Louise CooleyDepartment of Microbiology and Infectious Diseases, Royal Hobart Hospital, Hobart, Tasmania, Australia.
Ian G BarrWHO Collaborating Centre for Reference and Research on Influenza, Victorian Infectious Diseases Reference Laboratory at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.ORCID https://orcid.org/0000-0002-7351-418X Funding
Australian Government Department of Health, Disability and AgeingJapanese Ministry of Health, Labor, and Welfare 21HA2003Japanese Ministry of Health, Labor, and Welfare 24HA2005JSPS KAKENHI 18K10036
6 · The paper itselfAbstract
The emergence of viruses with reduced susceptibility to antivirals poses an ongoing risk which could limit their effectiveness. Here we report a cluster of A(H3N2) viruses detected in Tasmania, Australia, with a PA gene mutation A37T that showed mild reductions in susceptibility in vitro to baloxavir (3.47- to 16.33-fold increased EC
Indexed as
Antiviral AgentsDibenzothiepinsDrug Resistance, ViralInfluenza A Virus, H3N2 SubtypeInfluenza, HumanMorpholinesOxazinesPyridonesTriazinesAnimalsHumansMicrobial Sensitivity TestsRNA-Dependent RNA PolymeraseTasmaniaViral ProteinsAntiviral AgentsbaloxavirDibenzothiepinsMorpholinesOxazinesPA protein, influenza virusesPyridonesRNA-Dependent RNA PolymeraseTriazinesViral Proteinsantiviral susceptibilitybaloxavirinfluenza A viruses
Identifiers
PMID42778508
PMCPMC13601022
What OpenQuestion holds
Textmetadata
Read underepoch 390